Narrative Update: Minerva Price Target Revision
Analysts have raised their fair value estimate for Minerva from $7.62 to $7.85. This increase reflects modest improvements in projected revenue growth and a slightly lower discount rate.
What's in the News
- Minerva S.A. has been added to the Brazil Valor BM&FBOVESPA Index (Key Developments).
- A Special/Extraordinary Shareholders Meeting is scheduled for August 28, 2025, and will be held exclusively remotely on atlas agm in Brazil (Key Developments).
Valuation Changes
- Fair Value: Increased slightly from R$7.62 to R$7.85.
- Discount Rate: Decreased modestly from 21.86% to 21.66%.
- Revenue Growth: Increased marginally from 10.85% to 10.97%.
- Net Profit Margin: Decreased slightly from 1.89% to 1.87%.
- Future P/E: Increased from 14.40x to 14.89x.
Have other thoughts on Minerva?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.